Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) [Phase 2]
Phase 2 clinical trial evaluating azacitidine in combination with venetoclax for higher-risk chronic myelomonocytic leukemia is active/not r…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant [Phase 1]
A Phase 1 clinical trial update assessing olutasidenib for IDH1-mutated acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomo…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia [Phase 2]
This Phase 2 trial compares pacritinib to hydroxyurea in advanced proliferative chronic myelomonocytic leukemia and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. [Phase 2]
Phase 2 study evaluating olutasidenib in IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms [Phase 1]
This clinical trial update notes a Phase 1 study of Onvansertib for recurrent or refractory chronic myelomonocytic leukemia and myelodysplas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [Phase 2, Phase 3]
A phase 2/3 clinical trial is investigating venetoclax in combination with a fractionated busulfan conditioning regimen for high-risk acute …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluates venetoclax combined with ASTX727 (oral decitabine/cedazuridine) in treatment-naive high-risk myelodyspl…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders [Phase 2]
Phase 2 clinical trial update evaluating a geriatric assessment to guide treatment planning for older adults with myelodysplastic syndromes,…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) [Phase 1]
A Phase 1 clinical trial evaluating STX-0712 in patients with advanced hematologic malignancies is currently recruiting. The study includes …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer [Phase 2]
Phase 2 clinical trial evaluating FLAG-Ida chemotherapy followed by reduced-intensity total body irradiation and donor hematopoietic cell tr…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study evaluating the combination of venetoclax and azacitidine for relapsed or refrac…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [Phase 2]
A Phase 2 rollover study from Novartis continues Sabatolimab (MBG453) treatment for patients who completed a prior study, to assess continue…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies [Phase 1]
Hu8F4 is being studied in a Phase 1 trial for multiple advanced hematologic malignancies; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) [Phase 1, Phase 2]
This Phase I/II clinical trial is evaluating Axatilimab, a CSF1R monoclonal antibody, in combination with ruxolitinib for myelofibrosis and …
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts [Phase 2]
A Phase II trial is evaluating a combination regimen of cladribine and low-dose cytarabine with venetoclax, alternating with azacitidine and…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation [Phase 2]
A Phase 2 dose-expansion study evaluating a low-dose post-transplant cyclophosphamide/tacrolimus/ruxolitinib regimen for graft-versus-host d…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) [Phase 3]
A Phase 3 randomized trial evaluating IMM01 plus azacitidine versus placebo plus azacitidine in newly diagnosed chronic myelomonocytic leuke…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Personalized NK Cell Therapy in CBT [Phase 2]
A Phase 2 trial from MD Anderson is evaluating personalized NK cell therapy across several hematologic cancers. The study is currently recru…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse [Phase 1, Phase 2]
This clinical trial evaluates decitabine in combination with the FLAG-Ida chemotherapy regimen and total-body irradiation, followed by donor…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) [Phase 2]
Phase 2 study update for participants who previously took ASTX727 (oral decitabine/cedazuridine) that is currently enrolling by invitation.
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Two Step Haplo With Radiation Conditioning [Phase 2]
Phase 2 clinical trial update describing two-step haploidentical transplantation with radiation conditioning for hematologic diseases, curre…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]
This trial evaluates a targeted radiopharmaceutical (211At-BC8-B10) followed by an allogeneic donor stem cell transplant for relapsed or ref…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: AZD6738 for Patients With Progressive MDS or CMML [Phase 1]
Phase 1 clinical trial update of AZD6738 in patients with progressive myelodysplastic syndrome or chronic myelomonocytic leukemia; the study…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: NTX-301 in MDS/AML [Phase 1]
Phase 1 clinical trial update for NTX-301 in acute myeloid leukemia and myelodysplastic syndromes, including chronic myelomonocytic leukemia…